Check out our new video, which explains what the PanCareLIFE project is all about!
Project News and Updates.
SIOP Europe are hosting ‘Development of paediatric cancer medicines – Milestones and the Road Ahead Towards More Life-Saving Innovation’ for International Childhood Cancer Awareness Day 2017. The event is being held Tuesday 7 March 2017 in Brussels. Belgium.
You can submit abstracts now for the 49th Congress of the International Society of Paediatric Oncology, to be held 12 – 15 Oct 2017 in Washington, DC. The deadline is 28 March 2017.
The SIPO congress coincides with the annual Childhood Cancer International (CCI) Congress.
February 14 is International Childhood Cancer Day, which highlights the need for concerted global actions to address the growing challenge posed by this non-communicable disease.
The ICCD campaign’s ultimate goal and unified message is “Better access to Care for Children & Adolescents with Cancer Everywhere”. The 1800 healthcare professionals from 110 countries who are members of the International Society of Paediatric Oncology (SIOP) and the 187 member organizations of Childhood Cancer International (CCI), the largest non-profit patient support organization for childhood cancer ask everyone to come together in solidarity to make sure children and adolescents everywhere have the chance to survive cancer and live long, productive and meaningful lives.
We’re delighted to hear that a patient from our UK data provider Dr. Alison Leiper of the Great Ormond Street Hospital in London, has given birth after surgeons implanted ovary tissue taken when she was a child.
CREDIT: FERGUS WALSH/BBC
The 24-year-old is thought to be the first in the world to have a baby after having an ovary frozen before the onset of puberty.
Moaza Al Matrooshi, who gave birth in London, said the arrival of her baby son was “like a miracle”.
The UK breakthrough will give hope to thousands of other girls who are unable to conceive because their reproductive organs have been damaged by treatment for cancer and other diseases.
14 Dec 2016, The Telegraph, UK
Dr. Alison Leiper, Great Ormond Street Hospital
The final General Assembly of PanCareSurFup, PanCare’s first consortium, was held in Erice, Sicily in conjunction with the PanCare meeting to celebrate the 10th anniversary of the Erice Statement.
Erice is a stunning village of medieval houses, churches and monasteries perched 700 metres above the Mediterranean on Sicily’s north coast. The church of San Domenico has been transformed into a state of the art conference venue. The PanCareSurFup General Assembly meeting took place in the basement conference room. The consortium were able to take our coffee breaks in the stunning upper floor with a stupendous view. As part of the closing meeting, PanCareSurFup Coordinator Lars Hjorth was presented with a special Sicilian pottery piece by Riccardo Haupt to recognise Lars’ achievement in keeping the consortium on track for six years.
Riccardo Haupt presenting Lars Hjorth with Sicilian pottery piece
PanCareLIFE researchers at EMC, VUmc, AMC, PMC and UKM have published ‘Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study’, funded in part by PanCareLIFE.
European Journal of Cancer (2016) 69: 77, DOI: 10.1016/j.ejca.2016.09.023
You can register now for International Childhood Cancer Awareness Day (ICCD 2017), which takes place 07 Mar 2017 in Brussels at the European Parliament.
PanCareLIFE researchers from EMC and VUmc have published ‘Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss’ (Human Reproduction, Vol.32, No.1 pp. 193–200, 2017).
You can read the full open access publication here.
STUDY QUESTION: Is the long-term decline of ovarian function, as reflected by a decrease in serum anti-Müllerian hormone (AMH) concentration, accelerated over time in female childhood cancer survivors (CCS) as compared to healthy women of the same age?
SUMMARY ANSWER: The median decline of AMH levels in long-term female CCS is not accelerated and similar to that observed in healthy controls.
WHAT IS KNOWN ALREADY: Gonadal function is compromised in female CCS treated with chemotherapy and/or radiation therapy. Ovarian function is most compromised in survivors treated with total body irradiation, abdominal or pelvic irradiation, stem cell transplantation or high doses of alkylating agents.
STUDY DESIGN SIZE, DURATION: Longitudinal single-centre cohort study in 192 CCS in Rotterdam, The Netherlands, between 2001 and 2014.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum AMH levels of 192 adult female CCS were assessed, at least five years after cessation of treatment and at a follow-up visit with a median of 3.2 years (range: 2.1–6.0) later and were compared to the age-based P50 of AMH in healthy controls.
MAIN RESULTS AND THE ROLE OF CHANCE: Median AMH levels were below the P50 at both visit 1 (−0.59 µg/L) and at visit 2 (−0.22 µg/L). In women with a sustained ovarian function (AMH > 1.0 µg/L), the decline in AMH is similar to that in the normal population (difference in decline per year: −0.07 µg/L (range: −2.86 to 4.92), P = 0.75). None of the treatment modalities was correlated with a signifi- cant acceleration of decline of AMH per year.
LIMITATIONS REASONS FOR CAUTION: We selected CCS that visited our late effect outpatient clinic and who had two AMH levels available. It is conceivable that women without any apparent late effects of treatment as well as women with extreme late effects, which might be the ones with the largest impact on ovarian function, could be more likely to be lost to follow-up. However, general characteristics did not differ between the included and excluded patients.
WIDER IMPLICATIONS OF THE FINDINGS: While prospective longitudinal research is required to strengthen our findings, they may help physicians to counsel female CCS about their expected reproductive lifespan.
PanCareLIFE was featured in the Drogheda Life after our recent year 3 meeting, held in Drogheda. Ireland.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.